Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients

Inclusion Criteria: * Patients with renal graft since at least 1 year * Patients treated with ciclosporin or tacrolimus * Are at least 18 years old. * Glomerular filtration rate above 30 ml / min calculated using the MDRD formula * Among the 14 patients receiving ciclosporin: * The genotype is not a criterion for inclusion * Among the 14 patients with tacrolimus treatment: * 7 genotype ABCB1 3435CC, 7 genotype ABCB1 3435TT * Recent (1 month) residual concentration of tacrolimus between 5-10ng/ml * Recent (1 month) residual concentration of ciclosporin between 100-200ng/ml * For women : a negative pregnancy test (serum beta hCG) * Realization of a medical examination. * Informed consent and writing form. Exclusion Criteria: * Abnormal transaminases (AST and ALT above the ULN Laboratory). * Underlying Liver Disease (steatosis, cirrhosis, chronic hepatitis, the virus of hepatitis C or B). * Previous history of muscle disease (drug related especially the statin type). * Leukopenia (WBC \<3000/mm3). * Hemoglobin \<11g/dl. * Patient treated by erythropoetin (whatever its hemoglobin value). * Abnormal CPK (greater than the ULN Laboratory). * Prior intolerance to colchicine. * Regular intake of the following medications associated with rhabdomyolyses: antipsychotics, cholesterol lowering agents (statins or fibrates), zidovudine, antidepressants (selective inhibitor of serotonin reuptake) and lithium. * Patient (e) can not refrain from consuming grapefruit juice. * Patient (e) taking a tea based on St John's wort. * Taking drugs inducers of P-gp or CYP3A4 (rifabutin, rifampin, carbamazepine, phenytoin, phenobarbital, efavirenz, nevirapine, protease inhibitors, griseofulvin). * Taking drugs inhibitors of P-gp or CYP3A4 (quinidine, macrolide antibiotics, azole antifungals, protease inhibitors, amiodarone, diltiazem, verapamil). * Chronic diarrhea. * ABCB1 Genotype 3435CT for patients in the tacrolimus group. * Participation in another concurrent trial. * Patient (e) exclusion period of another trial. * Patient (e) having reached the maximum annual amount of compensation provided by law. * No affiliation to French social security scheme or without CMU.